Mpl is the receptor for thrombopoietin, the primary regulator of platelet production by megakaryocytes. Upon stimulation by its ligand, Mpl receptor induces proliferation and dierentiation of hematopoietic cell lines of various origins. In this paper, we show that Mpl is also able to transform FRE rat ®broblasts in the presence of MGDF (pegylated Megakaryocyte Growth and Development Factor), a modi®ed form of its ligand. We also demonstrate that upon MGDF stimulation Mpl receptor activates the classical transduction pathways described for hematopoietic cell lines in FRE cells. Introduction of Mpl deletion mutants in FRE cells allowed us to demonstrate that the C-terminal region of the Mpl intracytoplasmic domain, which is involved in hematopoietic dierentiation, is necessary for the transformation process. Within that region, site-directed mutagenesis showed that the Y112 residue, which is required for Shc phosphorylation, is essential for rat ®broblast transformation by Mpl/MGDF, suggesting the involvement of Shc in Mpl-mediated transformation. Interestingly, we showed that transformation correlated with strong and sustained MAPK activation. Neither Jak2, Stat3 nor Stat5 phosphorylation was sucient to induce the transformation process. Taken altogether, our results suggest the oncogenicity of Mpl in ®broblastic cells in the presence of its ligand.
Introduction
Mpl is the receptor for thrombopoietin, the primary regulator of platelet production by megakaryocytes (Kaushansky, 1995; Eaton and de Sauvage, 1997) . Upon stimulation by its ligand, Mpl receptor induces proliferation and dierentiation of hematopoietic cell lines of various origins (Gurney et al., 1995; Alexander et al., 1996; Morita et al., 1996; Porteu et al., 1996) . More recently, Mpl has also been shown to be involved in hematopoietic stem cell proliferation (Kimura et al., 1998; Solar et al., 1998) .
Mpl is a member of the hematopoietic growth factor receptor superfamily (Souyri et al., 1990; Vigon et al., 1992 Vigon et al., , 1993 Skoda et al., 1993) , and like other members of this family, such as the receptors for growth hormone, prolactin, erythropoietin, and granulocyte colony-stimulating factor, it is believed to homodimerize after ligand binding. Although devoid of intrinsic tyrosine kinase activity, upon Mpl-ligand stimulation the intracytoplasmic domain of Mpl promotes rapid tyrosine phosphorylation and activation of a number of intracellular proteins. These include members of the Janus family of protein kinases (Jaks), signal transducers and activators of transcription (Stats), Ras signaling molecules and mitogen-activated protein kinases (MAPKs), tyrosine phosphatases and the receptor itself (Miyakawa et al., 1995; Mu et al., 1995; Pallard et al., 1995; Sattler et al., 1995; Sasaki et al., 1995; Drachman et al., 1995; Rouyez et al., 1997) . A systematic study of Mpl-mediated signal transduction, using deletion and point mutants of the cytoplasmic domain, has indicated that the membraneproximal region, encompassing the box-1 and box-2 motifs conserved in the cytokine receptor family, is involved in cell proliferation and activation of the Jak/ Stat pathway, while the carboxy-terminal region is required for dierentiation (Alexander et al., 1996; Morita et al., 1996; Porteu et al., 1996; Takatoku et al., 1997; .
This latter region contains the two cytoplasmic tyrosine residues (Y112 and Y117) detectably phosphorylated in response to Mpl-ligand stimulation and important for Shc and Stat3 activation: the Y112 residue is critical for recruitment and phosphorylation of Shc, suggesting a role for Shc in the dierentiation process (Alexander et al., 1996; . This role was further documented by the introduction of a mutated Shc protein into murine myeloid 32Dcl3 cells engineered to express the Mpl receptor, which blocked Mpl-ligand-induced dierentiation (Hill et al., 1996) . Both Y112 and Y117 residues are candidates for partial recruitment and phosphorylation of Stat3 .
In the present study, we describe a new feature of the Mpl receptor, which is the ability to transform rat ®broblasts. Although the truncated oncogenic form of Mpl, v-mpl, was unable to transform NIH3T3 cells, we noticed rapid morphological changes in rat ®broblasts infected with the MPLV virus, which prompted us to check if full-length Mpl receptor could have the same eect. In the presence of Mpl-ligand we did indeed observe the transformation of FRE cells engineered to express the murine Mpl receptor, which demonstrated the oncogenicity of normal Mpl receptor expressed ectopically in rat ®broblasts. Mutants containing various deletions of the intracellular domain of Mpl were introduced into FRE cells, and the transduction molecules involved in the transformation were analysed. This study showed that in FRE cells, ligand binding is accompanied by the activation of the classical transduction pathways described for hemato-poietic cell lines, and allowed us to determine the Mpl cytoplasmic domains necessary for transformation.
Results

MPL transforms rat fibroblasts in the presence of its ligand
While looking for ®broblast cell lines capable of producing high amounts of MPLV virus (which contains the truncated, oncogenic form of Mpl receptor), we noticed that the NRK and FRE rat cell lines changed morphologically 24 ± 48 h after MPLV/F-MuLV infection. Cells became more fusiform, refractile, and seemed to lose contact inhibition. Such morphological alterations persisted over passages, and were not observed when the cells were infected with helper F-MULV virus alone ( Figure 1A ,B). Altogether these observations indicated that MPLV had transformed the FRE cells. In order to prove transformation formally, we tested anchorage independence of FRE MPLV/F-MuLV, as well as of parental FRE and FRE/F-MuLV cells, by plating them in soft agar. As shown in Table 1A , only FRE MPLV/F-MuLV cells grew in these conditions. When replated individually in liquid culture, FRE MPLV/F-MuLV colonies were able to grow, and kept their transformed features.
Since MPLV is a constitutively activated Mpl receptor, we decided to test whether full-length Mpl activated by its ligand exhibits a comparable transforming activity. We engineered a retroviral vector encoding the murine Mpl sequence, with a FLAG sequence in 5', and infected FRE cells with the resulting MSCV MPLwt virus. Mpl expression at the cell surface was analysed by¯ow cytometry using M1 anti-FLAG antibody ( Figure 2B ). When grown in regular culture medium (DMEM+10% FCS), FRE MPL cells looked similar to parental FRE cells. However, as early as 24 h after addition of 20 ng/ml of MGDF (pegylated Megakaryocyte Growth and Development Factor, a modi®ed truncated form of the Mpl ligand), cells looked more refractile and fusiform and had lost contact inhibition like FRE MPLV/F-MuLV cells (see Figure 1C,D) . This transformed morphology was observed as long as MGDF was present in the medium and reverted after MGDF removal. We next analysed the ability of FRE MPLwt cells to grow in an anchorage-independent manner by plating them in soft agar in the presence or absence of 50 ng/ml MGDF. FRE MSCV cells were used as controls. Only FRE MPLwt cells grown in the presence of MGDF generated colonies in soft agar (Table 1B) . Figure 1E ). This demonstrates that transformation is speci®cally mediated by Mpl receptor.
Our results show that Mpl receptor can transform rat FRE ®broblasts in the presence of its hormone and that transformation is strictly dependent on the presence of the ligand. Furthermore, the fact that vMpl, which contains very little of the Mpl extracellular domain (43 amino acids versus 462), is also able to transform rat ®broblasts suggests that transformation is mediated by Mpl intracellular domain activation.
Two regions of Mpl cytoplasmic domain are necessary for FRE cell transformation
In order to identify Mpl cytoplasmic regions involved in the transformation process, we introduced FLAG-MPL mutants containing various deletions of the intracellular domain (MPLD1, D2, D3, D4 and D3+4) (Figure 2A ) into the MSCV retroviral vector. FRE cells were infected with the resulting retroviruses and subjected to neomycin selection. Expression of deletion mutants was assessed by¯uorescence-activated cell sorter analysis. As shown in Figure 2B , all deletion mutants were quantitatively and correctly expressed at the surface of FRE cells.
The ability of each mutant to transform FRE cells was then tested after addition of MGDF ( Table 2 ). The morphology of FRE MPLD1-, MPLD2-and MPLD4-infected cells was unaltered, even in the presence of high concentrations of MGDF (up to 200 ng/ml). Two regions necessary for transformation were thus determined: one composed of the ®rst 70 amino acids (encompassing box 1 and box 2, shown to be important for Jak2 activation), and the second including the last 22 amino acids (involved in the recruitment and phosphorylation of Shc and in Stat3 activation).
Only MPLD3 cells became transformed in the presence of MGDF, indicating that the region between amino acids 71 and 94 was dispensable for the transformation process. Morphological alterations of these cells were even sharper than those observed in FRE MPLwt cells.
Interestingly, MPLD3+4 cells presented a transiently transformed morphology 24 h after addition of MGDF which disappeared as cells reached con¯uency.
Shc is involved in rat fibroblast transformation by Mpl/Mpl-ligand
In order to determine the transduction signals involved in the transformation process, we studied MPL signal transduction in FRE cells which express the MPLwt receptor or the dierent deletion mutants after addition of MGDF. As shown in Figures 3 and 4 , the tyrosine kinase Jak2, transcription factors Stat5 and Stat3, and the adaptor molecule Shc were phosphorylated in FRE MPLwt cells upon MGDF stimulation. This indicated that in rat ®broblasts, MPL receptor stimulation by MGDF activates the classical transduction pathways described in hematopoietic cell lines.
The MPLD3 receptor activated the same molecules as wild-type MPL in FRE cells, with the same or even higher eciency (Figures 3 and 4) .
As expected, among the mutants which did not transform ®broblasts, MPLD1 and MPLD2, which lack box 1 and box 2, respectively, did not induce Jak2 phosphorylation ( Figure 3A ) nor transduce any signal in FRE cells. In FRE MPLD4 and FRE MPLD3+4 cells, Jak2 was phosphorylated (less in FRE MPLD4 cells) in response to MGDF ( Figure 3A ), indicating that Jak2 per se is not sucient nor responsible for rat ®broblast transformation by Mpl/Mpl-ligand. The Stat5 and Stat3 factors were also phosphorylated in FRE MPLD4 cells, although at a lower level than that observed for FRE MPLwt cells ( Figure 3B ,C). Interestingly, almost no phosphorylated form of Stat5 was found in FRE MPLD3+4 cells ( Figure 3B ). In these cells, the level of activated Stat3 was identical to that observed for FRE MPLD4 cells ( Figure 3C ).
In contrast, Shc was not phosphorylated in FRE MPLD4 or FRE MPLD3+4 stimulated cells ( Figure  4 ). This suggested a role of this molecule in transducing transformation signals from Mpl. The region deleted in the MPLD4 mutant contains two tyrosine residues, Y112 and Y117, the former being required for Shc phosphorylation (Alexander et al., 1996; . We therefore engineered Mpl receptors in which either the Y112 or Y117 residue was mutated to phenylalanine (Y112F and Y117F, respectively). These mutants were transduced into FRE cells and analysed for their transforming potential. In the presence of MGDF, FRE MPLY112F cells did not change morphologically, while FRE MPLY117F cells had a transformed appearance comparable to that observed with FRE MPLwt cells. Like MPLwt, the MPLY117F receptor activated Jak2, Stat5 and Stat3, and Shc in FRE stimulated cells (Figures 3 and 4) . MPLY112F phosphorylated Jak2 ( Figure 3A ), Stat3 and Stat5 ( Figure 3B ,C), but not Shc (Figure 4) , further suggesting that the Shc molecular adaptor is involved in the transformation process.
Transformation by Mpl/MGDF is mediated by the Map kinase pathway
The phosphorylated Shc protein has been shown to induce the Ras-MAP kinases (Ras-MAPK) cascade through its interaction with the Grb2 adaptor protein.
We therefore examined Shc/Grb2 complex formation in FRE MPLwt cells and in FRE cells expressing Mpl mutants. As shown in Figure 4 , Grb2 was co- To assess the role of the MAPK pathway in the FRE transformation process, we ®rst tested the eect of the MEK inhibitor PD98059 on the ability of MGDF to transform FRE MPLwt cells. The inhibitor (100 mM, a concentration shown to have no toxic eect on FRE cells) was added to the medium 3 h before MGDF (50 ng/ml), and cell shape was monitored under the inverted microscope for 2 days. In the (7) of 50 ng/ml MGDF. Immunoprecipitates were analysed by Western blotting using anti-phosphotyrosine antibody (aP-Tyr). Blots were stripped and reprobed with the anti-Jak2 tyrosine kinase antibody (aJak2). (B) Stat5 phosphorylation in FRE MPL wt and MPL mutant cells. Whole cell extracts from serum-starved cells stimulated or not for 30 min with MGDF were analysed by Western blotting with an antibody raised against the phosphorylated form of Stat5 (aStat5-P). After stripping, blots were rehybridized with an anti-N-terminal Stat5 antibody (aStat5), which recognizes both Stat5A (p92) and Stat5B (p84). (C) Stat3 phosphorylation in FRE MPL wt and MPL mutant cells. Whole cell extracts from serum-starved cells stimulated or not for 30 min with MGDF were analysed by Western blotting with an anti-phosphorylated Stat3 antibody (aStat3-P). Blots were stripped and reprobed with anti-N-terminal Stat3 antibody (aStat3) which recognizes both Stat3a (p92) and Stat3b (p83) Figure 4 Induction of Shc tyrosine phosphorylation in FRE MPLwt and MPL mutant cells. Cells were serum-starved for 18 h, and incubated for 30 min in the presence (+) or absence (7) of 50 ng/ml MGDF. Immunoprecipitates were analysed by Western blotting using anti-phosphotyrosine antibody (aP-Tyr). Blots were stripped and reprobed with anti-Shc (aShc), and anti-Grb2 (aGrb2) antibodies, successively Oncogene Mpl/MGDF transformation of rat fibroblasts C Challier et al presence of PD98059, no change in cell morphology was observed, while the same cells presented the typical transformed appearance when grown in the presence of MGDF alone ( Figure 5A ). Analysis of ERK-1 and ERK-2 phosphorylation con®rmed that PD98059 inhibited ERK activation in FRE MPLwt cells in the presence of MGDF ( Figure 5B ). The same results were found with FRE MPLD3 and MPLY117F cells (data not shown).
We next analysed ERK-1 and ERK-2 phosphorylation in all Mpl deletion mutant-expressing cells. As shown in Figure 6A , marked ERK-1 and ERK-2 phosphorylation was observed in FRE MPLD3 cells after 30 min of MGDF stimulation, identical to that seen in FRE MPLwt cells, while weaker activation was detected in FRE MPL D4 and MPLY112F cells.
Kinetic studies showed strong and sustained phosphorylation of ERK-1 and ERK-2 in FRE MPLD3 ( Figure 6B ) and FRE MPLwt cells (data not shown). Intense activation was also observed in FRE MPLD3+4 cells, but it faded 2 h after MGDF addition ( Figure  6B ). As shown in Figure 6B , ERK-1 and ERK-2 activation was weaker and transient in FRE MPLD4 cells. These results indicate that strong and sustained MAP kinase activation by the C-terminal region of Mpl via Shc is responsible for rat ®broblast transformation by Mpl/Mpl-ligand.
Discussion
In this study, we report that v-mpl, the constitutively activated form of Mpl receptor, induces transformation of FRE rat ®broblasts. We further show that the murine Mpl receptor is able to induce the transformation of FRE cells in the presence of its ligand. We demonstrate that this transformation is ligand-dependent and mediated by the Mpl receptor. Transformation results in Mpl intracytoplasmic domain activation, which promotes rapid tyrosine phosphorylation and activation of many intracellular proteins. Stimulation of the Mpl receptor by MGDF in rat ®broblasts activates the transduction pathways described classically in hematopoietic cell lines, i.e. phosphorylation of Jak2, Stat5, Stat3, and Shc (see Figures 3 and 4) .
The ability of Mpl to transform rat ®broblasts was rather unexpected: (1) we had previously observed that MPLV, which contains the oncogenic truncated form of c-Mpl, was unable to induce transformation of NIH3T3 cells (Souyri et al., 1990) . Indeed, we found that addition of the Mpl-ligand to NIH3T3 cells expressing the Mpl receptor does not induce any morphological change. Although Mpl expression level at the surface of these cells was just as high as that detected on FRE MPLwt cells (as assessed by¯ow cytometry), weaker activation and phosphorylation of transduction molecules was detected upon MGDF stimulation (data not shown). This suggests that the FRE cell context eciently supports Mpl receptor activity, leading to transformation in the presence of its ligand. Such a dierential susceptibility of mouse NIH3T3 cells and rat ®broblasts to transformation has been already described in the case of the tyrosine kinase P210, the product of the Bcr-Abl oncogene. Among the hypotheses proposed to explain this dierence, it was suggested that NIH3T3 cells fail to express some factor required to interact with Bcr-Abl (Daley et al., 1987; Lugo and Witte, 1989) ; (2) ®broblast transformation has been demonstrated with most members of the tyrosine kinase receptor family, but not with the members of the growth factor receptor superfamily. As the only exception, the human granulocyte-macrophage colony-stimulating factor receptor (GM-CSF-R) has been reported to transform NIH3T3 cells in the presence of GM-CSF, but only when both a and b subunits were coexpressed in these cells (Areces et al., 1993) . As for Mpl, no interaction of this receptor with known common signaling subunits (gp130, IL-2-Rg, or the common b-chain of the GM-CSF, IL-3, and IL-5 receptors) has been reported, and upon binding the Mpl-ligand is believed to induce receptor homodimerization. We tested whether FRE cells could be transformed by other members of the cytokine receptor superfamily, such as the prolactin and erythropoietin receptors which are also composed of a single chain, but we did not observe any morphological alteration of FRE cells expressing these receptors, even in the presence of high concentrations of their respective ligands (data not shown). This transformation property is therefore an original characteristic of Mpl. Using deletion mutants of the Mpl cytoplasmic domain, we showed that MPLD4 was unable to transform rat ®broblasts in the presence of MGDF. This demonstrates that the C-terminal region of the Mpl intracytoplasmic domain, which is involved in the dierentiation of hematopoietic cell lines (Alexander et al., 1996; Morita et al., 1996; Takatoku et al., 1997) , is required for rat ®broblast transformation. We were also able to delineate a region, corresponding to the amino acids 71 ± 94 deleted in MPLD3, which is dispensable for the transformation of FRE cells. This region has been shown in many reports to inhibit Mplligand induced proliferation (Alexander et al., 1996; Porteu et al., 1996; Takatoku et al., 1997) . Interestingly, the MPL D3+4 mutant led to a transient transforming phenotype in the presence of MGDF. Since the dierence between this mutant and MPLD4 is the deletion of amino acids 71 ± 94, this observation suggests that this region might also have an inhibitory eect on the ®rst 70 amino acids of MPL intracytoplasmic domain.
The C-terminal region of the Mpl intracytoplasmic domain required for rat ®broblast transformation, and more precisely the tyrosine residue Y112, has been shown to be essential for recruitment and phosphorylation of Shc (Alexander et al., 1996; . Indeed, no Shc phosphorylation was observed in FRE MPLD4-or FRE MPLY112F-stimulated cells (Figure 5 ), which indicates that the Shc adaptor protein, which plays an important role in hematopoietic dierentiation, is also essential for rat ®broblast transformation by Mpl/MGDF.
Tyrosine phosphorylated Shc binds to the Grb-2/SOS complex, resulting in activation of the Ras-MAP kinase (Ras-MAPK) cascade. The MAPK pathway has recently been shown to play a key role during megakaryocytic dierentiation of erythroleukemic and megakaryocytic cell lines (Whalen et al., 1997; Rouyez et al., 1997; Melemed et al., 1997; Matsumura et al., 1999) , and also during normal megakaryocytic development (Rojnuckarin et al., 1999; Fichelson et al., 1999) . Implication of the MAPK pathway in ®broblast transformation has also been well documented, using ras or MEK inhibitors (Ljungdahl et al., 1998) , dominant-negative forms or constitutive mutants of MEK1 (Cowley et al., 1994) . Our results strongly suggest that the MAPK pathway is also involved in the transformation mediated by Mpl/ MGDF. First, we found that the MEK inhibitor PD98059 abolishes transformation of FRE MPLwt, FRE MPLD3 and FRE MPLY117F cells in the presence of MGDF. Although very speci®c, PD98059 has recently been shown to act as an inhibitor of cyclooxygenases (Borsch-Haubold et al., 1998), but we could rule this out as an explanation of the eect observed on FRE cells by using indomethacin, an inhibitor of both cyclooxygenases 1 and 2. Indeed, even at 100 mM, indomethacin was unable to inhibit FRE MPLwt, FRE MPLD3 or FRE MPLY117F cell transformation in the presence of MGDF. Second, we showed that the transformed phenotype was correlated with strong and sustained MAPK activation (MPLD3, Figure 6B ). Furthermore, although transient, ERK activation was substantial in FRE MPLD3+4 cells ( Figure 6B ), which present a weak and transient transformed morphology in the presence of MGDF. This observation indicates too that MAPK activation can be driven independently of the Shc pathway. Taken together, our results indicate that strong and sustained MAP kinase activation is respon- 
As expected, Jak2 activation, which has been described as one of the ®rst events triggered by the Mp1-ligand and is required for all subsequent downstream signaling , is also necessary for the transformation of FRE cells by Mp1: the deletion mutants MPLD1 and MPLD2, which lack the box1 and box2 motifs crucial for Jak2 activation (Alexander et al., 1996; Gurney et al., 1995) , prevented phosphorylation of Jak2 or any other signaling molecule in FRE cells and were unable to transform rat ®broblasts in the presence of MGDF. However, Jak2 activation is not sucient for transformation, as illustrated by the MPLD4 mutant, which displays a signi®cant level of Jak2 phosphorylation upon MGDF stimulation, but is unable to transform FRE cells.
Stats transcription factors are the major target proteins of Jak2, and Mp1 receptor activation results in the tyrosine phosphorylation of both Stat3 and Stat5 upon ligand binding (Miyakawa et al., 1996; Pallard et al., 1995; ). In our model, although not transformed in the presence of MGDF, FRE MPLY112F cells presented a level of Stat3 and Stat5 phosphorylation comparable to that observed in FRE MPLwt and FRE MPLY117F cells ( Figure 3B,C) , which suggests that neither activated Stat3 nor Stat5 is sucient for transformation (but does not rule out their participation though). In agreement with studies carried out on hematopoietic cells, we observed a decrease in Stat3 phosphorylation in FRE cells expressing mutant MPLD4, indicating that this region is necessary for Stat3 activation. For Stat5 however, our results in rat ®broblasts dier from those described for hematopoietic BaF3 cells (Drachman and Kaushansky, 1997b) , since Stat5 phosphorylation was barely detected in FRE MPLD3+4 cells in the presence of MGDF.
In summary, we describe here an original characteristic of Mp1, which is its ability to transform rat ®broblasts in the presence of its ligand. Not only do the Mp1 intracytoplasmic regions involved in the transformation correspond to the domains essential for hematopoietic dierentiation, but transformation also requires pathways involved in TPO-induced dierentiation of hematopoietic cell lines. Although Mp1's ability to transform ®broblasts depends on the cellular context, our results point to a potential oncogenic property of Mp1 in ®broblastic cells in the presence of its ligand.
Materials and methods
Antibodies and reagents
Rabbit polyclonal anti-ERK-1 (p44 MAPK) and anti-Stat3 (against the N-terminal domain) antibodies were from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA). Anti-Shc, anti-Stat5 (against the N-terminal domain) and anti-Grb2 antibodies were from Transduction Labs (Becton Dickinson, Le Pont de Claix, France), polyclonal active MAPK antibody was from Promega (CharbonnieÁ res, France), anti-phosphorylated Stat5 antibody from Zymed Laboratories Inc. (Clinisciences, Montrouge, France), anti-phosphorylated-Stat3 antibody from New England Biolabs Inc. (Ozyme, Montigny-le-Bretonneux, France). The rabbit anti-Jak2 polyclonal antibody was from Upstate Biotechnology, Inc (Euromedex, Souelweyersheim, France). Anti-phosphotyrosine monoclonal antibody 4G10 was a gift from B. Drucker (Portland, OR, USA). Goat anti-mouse or rabbit Ig F(ab') 2 antibodies conjugated with horseradish peroxidase (HRP) were from Amersham Life Science (Les Ulis, France). The puri®ed IgG1 monoclonal antibody speci®c for a FLAG tag sequence epitope (M1), used for immuno¯uorescence, was a gift from D Cosman (Immunex, Seattle, WA, USA). Fluorescein isothiocyanate (FITC) conjugated goat F(ab') 2 fragments speci®c for mouse immunoglobulin G were from Sigma (StQuentin Fallavier, France).
Recombinant human MGDF (pegylated megakaryocyte growth and development factor, a modi®ed truncated form of the Mp1 ligand) was a gift from Amgen (Thousand Oaks, CA, USA).
Soluble mouse Mpl-Fc cDNA, kindly provided by D. Cosman (Immunex, Seattle, WA, USA), was introduced into the pEF-BOS plasmid (Mizushima and Nagata, 1990) . Soluble MPL receptor was produced after transient transfection of COS cells. The amount of COS cell supernatant used in all experiments corresponded to the concentration of soluble receptor able to fully inhibit the proliferation of UT7 cells expressing the murine MPL receptor in the presence of 20 ng/ml MGDF.
The speci®c MEK inhibitor PD98059 (Dudley et al., 1995) was from New England Biolabs Inc. A 10 mM stock solution was prepared in dimethylsulfoxide (DMSO).
Plasmid constructs and retrovirus production
A 2 kb fragment, corresponding to the murine full-length Mpl cDNA coding sequence with a FLAG epitope tag sequence at the N-terminus , was inserted at the XhoI site of the retroviral vector MSCV carrying the neomycin resistance gene (Hawley et al., 1994) (kindly provided by R Hawley). Previously described intracytoplasmic truncation mutants MPLD1, MPLD2, MPLD3, MPLD4 (Porteu et al., 1996) , as well as truncation mutant MPLD3+4 (Figure 2A ), were also introduced in the MSCV vector. Receptor fragments bearing single tyrosine ? phenylalanine substitutions were generated from the MSCV MPL wild-type (wt) sequence, using the Transformer TM sitedirected mutagenesis kit (Clontech Inc., Ozyme) with oligonucleotides incorporating tyrosine ? phenylalanine codon changes: 5'-CCACTCCTTCCTACCACTAAG-3' for MPL Y112F, and 5'-CCACTAAGCTTTTGGCAGCA-GCC-3' for MPL Y117F. DNA sequencing was subsequently carried out, in order to con®rm these two point mutations and to exclude additional alterations.
MSCV vectors encoding MPLwt or mutant MPL receptors were transfected transiently into the ecotropic packaging cell line BOSC 23 (kindly donated by Warren Pear), as described by Pear et al. (1993) . Forty-eight hours post-transfection, virus-containing supernatants were harvested and ®ltered through 0.45 mm-pore-diameter sterile ®lters. After titration on NIH3T3 cells, viral stocks were aliquoted and stored at 7708C. All viruses used in this study had a titer around 1610 6 neo R c.f.u./ml. Original stocks of MPLV/F-MuLV (Souyri et al., 1990) and F-MuLV (Oli et al., 1980) were propagated in NIH3T3 cells.
Cell culture and infection
FRE, a ®broblast line of the 3T3 type established from Fisher rat embryo cells (Seif and Cuzin 1977) , was maintained in Glutamax Dulbecco's modi®ed Eagle's medium (DMEM) (GIBCO ± BRL Life Technologies, Cergy Pontoise, France) supplemented with 10% heat-inactivated fetal calf serum (FCS) (Dutscher, Brumath, France). Cells were grown at 378C in a 5% CO 2 incubator, and split 1 : 10 every 3 ± 4 days.
Retroviral infections were performed after treatment of FRE cells with 20 mg/ml DEAE dextran (Pharmacia Biotech., Uppsala, Sweden), as previously described (Souyri et al., 1987) . Twenty-four hours after infection, cells were cultured in selective medium containing 500 mg/ml geneticin (GIB-CO ± BRL, Life Technologies). After 2 weeks of selection, Mp1 expression was assessed by¯ow cytometry.
Flow cytometric analysis of MPL expression
Mpl expression on FRE MPLwt and FRE MPL mutants was analysed by indirect immuno¯uorescence using the M1 monoclonal anti-FLAG antibody. Cells were dissociated with a non-enzymatic buer (GIBCO ± BRL) and washed twice in phosphate-buered saline (PBS) with 1% bovine serum albumin (PBS-BSA). After counting, 10 5 cells were incubated for 30 min with M1 (10 mg/ml) in the presence of 1 mM CaCl 2 . Cells were then washed twice with PBS-BSA+1 mM CaCl 2 and incubated with FITC-conjugated goat anti-mouse IgG (1 : 200) for another 30 min. After two washes, cells were analysed for¯uorescence on an ELITE¯ow cytometer (Coulter Corp, Miami, FL, USA).
Transformation analysis of FRE cells
Parental and infected FRE cells were plated in 6-well plates, and MGDF was added to the medium. Cell morphology was analysed under an inverted microscope 24 and 48 h later, after May ± GruÈ nwald ± Giemsa staining.
For soft agar assays, 2610 4 and 10 5 cells were plated in 60-mm dishes in 2 ml of 0.3% agar (Difco) in DMEM+10% FCS+50 ng/ml MGDF. Plates were incubated at 378C in the presence of 7% CO 2 . Soft agar plates were fed once a week with 2 ml of 0.3% agar containing DMEM with or without 50 ng/ml MGDF. Colonies were scored 15 days later. Only colonies which contained more than 20 cells were considered positive.
Immunoprecipitation and Western blotting analysis
Cells were serum-starved by overnight incubation in Iscove's Dulbecco's modi®ed Eagle's medium (IMDM) (GIBCO ± BRL) containing 0.4% deionized BSA and 25 mg/ml ironloaded human transferrin (Sigma). 20610 6 cells were subsequently stimulated in IMDM with or without 50 ng/ ml MGDF for 30 min at 378C. Stimulation was stopped with ice-cold PBS containing 50 mM sodium vanadate. Cells were solubilized with lysis buer containing 1% Brij 98 (Sigma) (lysis buer: 10 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, 10% glycerol, 1 mM sodium vanadate, 0.02% NaN 3 and protease inhibitors from Roche Diagnostics, Meylan, France). After 15 min on ice, extracts were centrifuged for 15 min at 27 000 g and supernatants were used for immunoprecipitation. Immunoprecipitating antibodies (antiJak2 and anti-Shc) were incubated with the solubilized cell extracts for 1 h at 48C and immune complexes were collected by incubation with protein G-Sepharose (Pharmacia Biotech) for 1 h at 48C. Sepharose beads were washed twice with lysis buer containing 1% detergent, twice with lysis buer with 0.1% detergent, and subjected to sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS ± PAGE).
Stat3 and Stat5 phosphorylation studies as well as the MAPK activation kinetic study were performed directly with whole cell extracts by loading on SDS-polyacrylamide gels the lysates from 5610 5 cells, stimulated or not with 50 ng/ml MGDF for 30 min and for various times at 378C.
Proteins were transferred to nitrocellulose membranes (Protran BA 85, Schleicher and Schuell, Cera Labo, Ecquevilly, France), blocked in Tris-buered saline (20 mM Tris, pH 7.4, 150 mM NaCl) containing 0.1% Tween 20 and 5% skim milk, and probed with the antibodies (either antiphosphotyrosine, anti-active MAPK, anti-phosphorylated Stat3 or anti-phosphorylated Stat5). Proteins were visualized by enhanced chemiluminescence (Amersham) after incubation with secondary HRP-conjugated antibody. Blots were stripped with 2% SDS, 100 mM 2-mercaptoethanol, 62.5 mM Tris HCl pH 6.8 for 30 min at 568C, then blocked again, washed and re-probed with antibodies to either Jak2, Shc, Grb-2, ERK-1, Stat3 or Stat5.
